相关实验视频
Updated: May 12, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
孕期自动化胰岛素器件的供应商观点以及在临床实践中实施的考虑因素
1Division of Endocrinology, Diabetes, and Metabolism, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Journal of diabetes science and technology
|May 8, 2025
概括
混合闭环 (HCL) 和先进的混合闭环 (AHCL) 系统在怀孕期间对1型糖尿病 (T1D) 的管理有希望. 需要进一步的研究来优化它们的使用,并解决监管差距,以改善孕产妇和新生儿的结果.
科学领域:
- 内分泌学 在内分泌学.
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 糖尿病 技术 技术
背景情况:
- 在1型糖尿病 (T1D) 中的怀孕与母亲和新生儿的不良结果有关.
- 糖尿病技术的进步,包括混合闭环 (HCL) 和先进的混合闭环 (AHCL) 系统,改善了T1D管理.
- 患有T1D的孕妇仍然是需要进一步调查的高风险群体,特别是在先进的糖尿病管理系统方面.
研究的目的:
- 审查现有的关于在T1D复杂的怀孕中使用闭环系统的证据.
- 讨论在怀孕期间使用HCL/AHCL系统的含义和考虑因素.
- 突出不同地区当前的监管格局和这些系统的非标签性使用.
主要方法:
- 对评估T1D孕妇闭环系统的研究的文献综述.
- 对血糖控制,孕产妇和新生儿结局数据的分析.
- 讨论妊娠所需的系统特异性益处,局限性和辅助技术.
主要成果:
- 现有的试验表明,关于闭环系统在怀孕期间进行血糖控制的临床益处,结果各不相同.
- 一个AHCL系统在英国,欧洲和澳大利亚得到批准,但在美国没有FDA批准的系统用于怀孕.
- 在美国,非标签使用往往需要额外的策略来达到目标葡萄糖水平.
结论:
- 闭环系统,包括HCL/AHCL,可以减少与每日多次注射或传感器增强疗法相比,T1D孕妇的护理负担.
- 这些系统可能有助于实现更严格的葡萄糖控制,这在怀孕期间至关重要.
- 进一步的研究和监管批准至关重要,以促进在T1D怀孕中安全有效地使用闭环系统.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Insulin: Dosing Regimen and Adverse Effects
127
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
127
Insulin Formulations: Types and Delivery
143
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
143
Pathophysiology of Diabetes
813
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
813
Diabetes: Management and Pharmacotherapy
212
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
212
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K

